Russell Investments Group’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-44,757
| Closed | -$1.8M | – | 4379 |
|
|
2026
Q1 | $1.8M | Buy |
44,757
+34,759
| +348% | +$749K | ﹤0.01% | 1931 |
|
|
2025
Q4 | $251K | Buy |
9,998
+97
| +1% | +$2.28K | ﹤0.01% | 2759 |
|
|
2025
Q3 | $224K | Sell |
9,901
-24
| -0.2% | -$560 | ﹤0.01% | 2772 |
|
|
2025
Q2 | $172K | Sell |
9,925
-28,978
| -74% | -$536K | ﹤0.01% | 2688 |
|
|
2025
Q1 | $851K | Buy |
38,903
+32,796
| +537% | +$906K | ﹤0.01% | 2101 |
|
|
2024
Q4 | $195K | Buy |
6,107
+2,876
| +89% | +$86.5K | ﹤0.01% | 2545 |
|
|
2024
Q3 | $93.2K | Sell |
3,231
-1,251
| -28% | -$46.3K | ﹤0.01% | 2670 |
|
|
2024
Q2 | $172K | Buy |
4,482
+896
| +25% | +$40.6K | ﹤0.01% | 2518 |
|
|
2024
Q1 | $211K | Buy |
3,586
+3,330
| +1,301% | +$212K | ﹤0.01% | 2431 |
|
|
2023
Q4 | $15.3K | Sell |
256
-35,215
| -99% | -$1.79M | ﹤0.01% | 2781 |
|
|
2023
Q3 | $1.35M | Sell |
35,471
-102,056
| -74% | -$4.48M | ﹤0.01% | 1770 |
|
|
2023
Q2 | $12.5M | Sell |
137,527
-673
| -0.5% | -$58.1K | 0.02% | 664 |
|
|
2023
Q1 | $9.12M | Buy |
138,200
+66,325
| +92% | +$3.83M | 0.02% | 806 |
|
|
2022
Q4 | $3.72M | Sell |
71,875
-16,265
| -18% | -$863K | 0.01% | 1247 |
|
|
2022
Q3 | $6.02M | Buy |
88,140
+40,082
| +83% | +$2.37M | 0.01% | 966 |
|
|
2022
Q2 | $2.17M | Buy |
48,058
+309
| +0.6% | +$14.1K | ﹤0.01% | 1546 |
|
|
2022
Q1 | $2.42M | Sell |
47,749
-60,202
| -56% | -$2.66M | ﹤0.01% | 1543 |
|
|
2021
Q4 | $5.1M | Sell |
107,951
-16,483
| -13% | -$649K | 0.01% | 1239 |
|
|
2021
Q3 | $4.1M | Buy |
124,434
+48,126
| +63% | +$2.7M | 0.01% | 1365 |
|
|
2021
Q2 | $4.82M | Sell |
76,308
-18,663
| -20% | -$963K | 0.01% | 1376 |
|
|
2021
Q1 | $4.07M | Buy |
94,971
+53,952
| +132% | +$2.55M | 0.01% | 1462 |
|
|
2020
Q4 | $2.35M | Sell |
41,019
-51,342
| -56% | -$2.17M | ﹤0.01% | 1669 |
|
|
2020
Q3 | $2.78M | Buy |
92,361
+57,940
| +168% | +$1.73M | 0.01% | 1477 |
|
|
2020
Q2 | $1.12M | Buy |
34,421
+12,492
| +57% | +$401K | ﹤0.01% | 1987 |
|
|
2020
Q1 | $587K | Buy |
+21,929
| New | +$779K | ﹤0.01% | 2108 |
|
|
2019
Q1 | – | Sell |
-57,478
| Closed | -$758K | – | 2908 |
|
|
2018
Q4 | $758K | Sell |
57,478
-2,936
| -5% | -$45K | ﹤0.01% | 2125 |
|
|
2018
Q3 | $1.07M | Buy |
60,414
+10,360
| +21% | +$191K | ﹤0.01% | 2082 |
|
|
2018
Q2 | $1.1M | Hold |
50,054
| – | – | ﹤0.01% | 2075 |
|
|
2018
Q1 | $1.11M | Buy |
+50,054
| New | +$984K | ﹤0.01% | 2168 |
|
Other funds holding APLS
Russell Investments Group's APLS Position: Q2 2026 in Review
Russell Investments Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 44,757 shares — an estimated $1.8M sold.
Russell Investments Group first reported a position in APLS in Q1 2018 and held it in 29 quarters. The position peaked at $12.5M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Russell Investments Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Russell Investments Group sold 44,757 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.8M.
- Russell Investments Group first reported a position in Apellis Pharmaceuticals in Q1 2018 and held it in 29 quarters.
- Russell Investments Group's Apellis Pharmaceuticals position peaked at $12.5M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.